Table 3.
Patient characteristics.
| Total | 105 | |
|---|---|---|
| Age | median: 51 years (18 – 83 years) | |
| Menopausal status | premenopausal | 47 (45%) |
| perimenopausal | 16 (15%) | |
| postmenopausal | 42 (40%) | |
| Histologic finding | ductal | 77 (73%) |
| lobular | 14 (13%) | |
| other | 13 (12%) | |
| unknown | 1 (1%) | |
| Tumor grading | G1 | 8 (8%) |
| G2 | 46 (44%) | |
| G3 | 49 (47%) | |
| unknown | 2 (2%) | |
| Tumor size pre-NACT | cT1a-cT1c | 24 (23%) |
| cT2 | 65 (62%) | |
| > cT2 | 15 (14%) | |
| unknown | 2 (2%) | |
| Nodal status pre-NACT | cN0 | 56 (53%) |
| cN1 | 42 (40%) | |
| cN2, cN3 | 7 (7%) | |
| Tumor size post-NACT | ypTis, ypT0 | 27 (26%) |
| ypT1a | 10 (10%) | |
| ypT1b, ypT1c | 32 (31%) | |
| ypT2 | 27 (26%) | |
| > ypT2 | 8 (8%) | |
| unknown | 1 (1%) | |
| Nodal status post-NACT | yN0 | 68 (65%) |
| yN1 | 26 (25%) | |
| yN2, yN3 | 10 (10%) | |
| unknown | 1 (1%) | |
| Estrogen receptor | pos | 74 (71%) |
| neg | 31 (30%) | |
| Progesterone receptor | pos | 66 (63%) |
| neg | 39 (37%) | |
| HER2 status | pos | 30 (29%) |
| neg | 75 (71%) | |
| Tumor subtype (IHC) | ER-, PR-, HER2- | 20 (19%) |
| ER-, PR-, HER2+ | 9 (9%) | |
| ER+/PR+, HER2- | 54 (51%) | |
| ER+, PR+, HER2+ | 22 (21%) | |
| NACT regimen | CTX | 70 (67%) |
| CTX + T | 17 (16%) | |
| CTX + T + L | 7 (7%) | |
| CTX + A | 4 (4%) | |
| HTX | 7 (7%) | |
| CTC pos | pre-NACT | 23 (22%) |
| post-NACT | 9 (9%) | |
| SL-CTC pos | pre-NACT | 35 (33%) |
| post-NACT | 11 (11%) | |
| Response | complete remission | 22 (21%) |
| partial remission | 73 (70%) | |
| no remission | 8 (8%) | |
| unknown | 2 (2%) | |
| Survival | OS | median: 52 months (4 – 82 months) |
| alive | 97 (92%) | |
| dead | 8 (8%) | |
| Recurrence | 3-year PFS | median: 34 months (4 – 36 months) |
| alive without relapse | 83 (79%) | |
| relapse | 8 (8%) | |
| unknown | 14 (13%) |
A – Avastin, CTC – Circulating tumor cells, CTX – chemotherapy, ER – estrogen receptor, HER2 – human epidermal growth factor receptor-2, HTX – hormonal therapy, L – Lapatinib, NACT – neoadjuvant chemotherapy, neg – negative, OS – overall survival, PFS – progression-free survival pos – positive, PR – progesterone receptor, SL-CTC – stem cell-like circulating tumor cell, T – Trastuzumab.